Skip to main content
Premium Trial:

Request an Annual Quote

Celemics, Strand Life Sciences Partner on Integrated Platform for NGS Analysis

NEW YORK – Celemics, a Korean manufacturer of targeted capture kits for next-generation sequencing, is combining its bioinformatics pipeline with analytics technology from Strand Life Sciences to help researchers go from sample to report using a single technology platform.

Under terms of the partnership, Bengaluru, India-based Strand Life Sciences will integrate the Celemics pipeline into its StrandOmics tertiary analysis platform. This integrated offering will include assay-specific variant filters to provide "guaranteed" clinical-grade data compliance for researchers in cancer and rare diseases, according to the companies.

"With our … track record of running NGS labs as well as interpretation support for genetic tests, we are excited to partner with Celemics to help bring their cancer, inherited cancer, and rare disease panels to the market," Strand Life Sciences CEO Ramesh Hariharan said in a statement.

"[Strand's] expertise in the engineering of NGS systems and long track record with the instrument and diagnostic companies will be valuable in accelerating our path to market integration," added Hyoki Kim, cofounder and CEO of Seoul, South Korea-based Celemics.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more